Greater tumor-infiltrating lymphocyte density is associated with improved overall survival outcomes in patients with ...
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...
Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Dr Kshitij Joshi and Dr Vashishth Maniar, two of the oncologists-turned-cofounders of MOC, tell Moneycontrol how the firm has ...
Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for select patients.
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...
Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).